William Blair analyst Andy Hsieh maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today. The ...
Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback